United States

Selecta, Sanofi to develop antigen-specific immunotherapies for life-threatening allergies

Friday, November 30, 2012 10:55 AM

Selecta Biosciences, a Watertown, Mass.-based clinical-stage biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, has entered into a strategic global collaboration with global healthcare company Sanofi to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies.

More... »

Rib-X Pharmaceuticals closes first tranche in $67.5M financing

Friday, November 30, 2012 10:28 AM

Rib-X Pharmaceuticals, a New Haven, Conn.-based biopharmaceutical company developing new antibiotics to treat serious and life-threatening infections, has closed the first tranche of a $67.5 million Series 2 preferred stock financing. A second tranche is anticipated to close around the end of 2012.

More... »

Aptiv Solutions opens new office

Thursday, November 29, 2012 01:52 PM

Reston, Va.-based Aptiv Solutions, a biopharmaceutical and medical device development services company with a focus on adaptive clinical trial design, simulation and execution, opened a new office in Durham, N.C., combining offices with its subsidiary Trio Clinical Resourcing.

More... »

Abbott board approves separation of AbbVie

Thursday, November 29, 2012 01:46 PM

The board of directors of Illinois-based Abbott has approved the separation of its research-based pharmaceuticals business, to be known as AbbVie, and declared a special dividend distribution of all outstanding shares of AbbVie common stock.

More... »

FDA approves Cometriq to treat rare type of thyroid cancer

Thursday, November 29, 2012 08:00 AM

The FDA has approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body.

More... »

Curis licensed IAP inhibitor GDC-0917 from Genentech

Wednesday, November 28, 2012 01:54 PM

Curis, a Lexington, Mass.-based drug development company focused on targeted small molecule drug candidates for cancer treatment, has licensed from San Francisco-based Genentech, a member of the Roche Group, exclusive worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins.

More... »

IntelliCell BioSciences inks research agreement with Rutgers’ N.J. Center for Biomaterials

Wednesday, November 28, 2012 11:16 AM

IntelliCell BioSciences, a regenerative medicine company developing novel technologies that address the regenerative, curative and preventative conditions of disease states with high unmet clinical needs, has entered a sponsored research agreement with the New Jersey Center for Biomaterials at Rutgers, the state university of New Jersey.

More... »

Rhythm expands Series B financing to $33M with Pfizer investment

Wednesday, November 28, 2012 10:48 AM

Rhythm, a Boston-based biotechnology company developing peptide therapeutics that for metabolic diseases, has raised an additional $8 million to complete a $33 million Series B financing.

More... »

CRA enters strategic alliance with Quintiles

Tuesday, November 27, 2012 11:42 AM

Tempe, Ariz.-based Clinical Research Advantage (CRA), a community-based network of clinical trial sites, has entered into a strategic agreement  with CRO Quintiles to facilitate a higher level of clinical trial participation with an emphasis on safety, improved study efficiencies and quality data.

More... »

FDA issues draft guidance for IRBs

Tuesday, November 27, 2012 11:28 AM

The FDA on Nov. 20 issued a draft guidance titled Draft Guidance for IRBs, Clinical Investigators and Sponsors--IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed.

More... »